Results from a clinical trial have revealed that Abbott’s HeartMate 3 left ventricular assist device (LVAD) demonstrated superiority over the HeartMate 2 LVAD in the long-term treatment of end-stage heart failure.
Heart pump technology 2019
The results, posted at the 68th American College of Cardiology Scientific Session on 17 March, of the MOMENTUM-3 trial have been cited as promising. Experts say the results demonstrate that further engineering by medical device manufacturers can produce a significant and positive impact on the treatment options for patients with end-stage heart failure.
Go deeper with GlobalData
Abbott’s MagLev pump technology, which is used in the HeartMate 3, is thought to be responsible for the reduction of many severe complications of end-stage heart failure treatment, such as stroke, thrombosis and re-operations for pump replacement.
As such, the device has been established as a clear choice for patients who are unsuitable for heart transplants and who do not respond to other treatments. The rate of stroke was more than 50% lower in the patient pool with the HeartMate 3 after two years. Abbott’s HeartMate 3 LVAD device has also demonstrated reduced hospitalisation time and vastly reduced blood clotting.
These combined findings are an important step toward reducing the costs associated with end-stage heart failure management and will drive the adoption of the implantable HeartMate 3 in developed and developing countries alike.
As newly engineered LVAD devices continue to demonstrate lower risks of complications, re-operations, and hospitalisations, GlobalData expects that the global market for implantable LVADs being used as destination therapies in the treatment of end-stage heart failure will continue to grow over the next decade.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
